CEO & Co-Founder
Caitlyn Miller, PhD, is CEO and Co-Founder of TwoStep Therapeutics, where she leads the company’s mission to bring innovative targeted therapies to patients. Dr. Miller received her PhD in Bioengineering from Stanford University in the labs of Dr. Carolyn Bertozzi and Dr. Jennifer Cochran. During her PhD and postdoctoral work, Dr. Miller played a pivotal role in advancing technology that is now integrated into TwoStep’s therapeutic pipeline. Dr. Miller then joined the Stanford Innovative Medicines Accelerator as an Entrepreneur-In-Residence, where she led the spinout of TwoStep Therapeutics. Under her leadership, TwoStep is advancing a pipeline of peptide-based drug conjugate and radioligand programs, with a first clinical trial planned for the second half of 2026.
VP, Clinical
Joy Geallis is VP, Clinical at TwoStep Therapeutics, bringing over a decade of expertise in advancing programs from preclinical research to Phase I-III trials. Her patient-focused approach and proven track record in clinical development encompass trial design, execution, and regulatory filings. Prior to joining TwoStep Therapeutics, she served as Vice President of Clinical at Immunitas Tx, where she successfully led the development of the lead program into a Phase I/II trial. She has also held pivotal roles at Astellas, Xeris Biopharma, and Northwestern University, where she demonstrated her expertise in strategic planning, cross-functional collaboration, and driving progress in clinical programs.
VP, Radiopharmaceutical Clinical Development
Nicolas Salem, PhD, is VP, Radiopharmaceutical Clinical Development at TwoStep Therapeutics. Dr. Salem joined TwoStep to lead the clinical development of the company’s radioligand program and brings over 15 years of experience in drug discovery and development in both biotech and large pharmaceutical companies. As a clinical imaging expert with a patient-centric focus and a deep commitment to operational excellence, Dr. Salem has contributed to the design and conduct of multiple Phase 0-4 trials for small molecule, immuno-oncology and therapeutic radiopharmaceuticals. Prior to joining TwoStep, Dr. Salem served as Executive Director, Clinical Imaging at Mariana Oncology, a Novartis company, where he designed and oversaw the conduct of Ph0 and Ph1 studies in support of two radiopharmaceutical programs. Dr. Salem also held a Senior Director, Clinical Imaging role at Bayer and scientist roles at Biogen and Takeda Pharmaceuticals. Dr. Salem received his PhD in Biomedical Engineering from Case Western Reserve University.
VP, CMC
Kevin Roland is VP, CMC at TwoStep Therapeutics, bringing more than 15 years of experience in CMC and radiopharmaceutical development to the role. With deep expertise in radiochemistry and a pragmatic, execution-focused approach, Mr. Roland leads the company’s CMC strategy across its pipeline of peptide-based radioconjugates and drug conjugates. Over the course of his career, he has built and led end-to-end CMC strategies for peptides, biologics, and small molecule-based radiopharmaceuticals, including the design and qualification of cGMP facilities, development of radiopharmaceuticals, and orchestration of global CDMO networks. His leadership has enabled multiple clinical program launches (e.g., 225Ac-PSMA-I&T), product commercializations (e.g., Neuraceq), and company acquisitions. Prior to joining TwoStep, Mr. Roland served as Senior Vice President of CMC Process Development at Abdera Therapeutics. He has also held senior CMC leadership roles at small and mid-sized biotech companies, such as Fusion Pharmaceuticals (acquired by AstraZeneca) and Isologic (now Pharmalogic).
Director, R&D Operations
Yash Agarwal, PhD, is Director, R&D Operations at TwoStep Therapeutics, leading preclinical research and operations. As a member of the founding team, Dr. Agarwal brings extensive expertise and leadership to the organization. Prior to joining TwoStep, he contributed to advancing cell therapies at GentiBio. Dr. Agarwal’s journey in biological engineering began during his doctoral studies at Massachusetts Institute of Technology (MIT), where he developed an innovative approach to improve the efficacy and safety of cancer immunotherapies in the labs of Dr. Dane Wittrup and Dr. Darrell Irvine, leading to notable publications and patents in the field.
Senior Scientist
Caleb Perez, PhD, is a Senior Scientist at TwoStep Therapeutics, where he supports the preclinical research and development of TwoStep’s therapeutic pipeline. Dr. Perez received his PhD in Biological Engineering from MIT, where he worked under Dr. Michael Birnbaum to engineer high-throughput platforms to optimize T cell-based immunotherapies. Prior to his doctoral studies, Dr. Perez conducted research as a Fulbright Scholar at the Ecole Polytechnique Federale de Lausanne (EPFL) in Switzerland, where he studied new modalities for dendritic cell cancer vaccines. Throughout his career, Dr. Perez has remained committed to the clinical translation of novel therapeutics that improve the lives of cancer patients.
Scientist II
Lucian Tomaz, PhD, is a Scientist II at TwoStep Therapeutics, where he supports the development of targeted cancer therapeutics through translational assay development and preclinical research. Dr. Tomaz completed his postdoctoral training at Stanford University, where he investigated cytoskeletal mechanisms involved in epithelial cell differentiation and tissue architecture. He received his PhD in Singapore through the A*STAR Singapore International Graduate Award, with research focused on investigating cellular mechanisms of stem cell differentiation, epithelial tissue organization, and tumor development. His work has combined in vivo disease models, in vitro cell and organoid systems, CRISPR-based approaches, histology, IHC/IF, and advanced microscopy to study biomarker expression and protein localization in developing tissues and tumors. With broad academic and industry research experience and ASCP-certified histotechnology expertise, Dr. Tomaz brings deep knowledge of IHC/IF assay development, antibody validation, and tissue-based analysis to TwoStep’s pipeline.
Executive Assistant
Kayla Luna is the Executive Assistant at TwoStep Therapeutics, supporting the CEO and senior leadership team. With extensive experience supporting executives across biotech and nonprofit organizations, she brings a proactive and detail-oriented approach to executive operations, including calendar and travel management, board coordination, and event planning. She plays a key role in improving efficiency, managing high-level logistics, and coordinating cross-functional priorities with discretion and care.
Co-Founder
Jennifer Cochran, PhD, is a Co-Founder of TwoStep Therapeutics and is the Addie and Al Macovski Professor of Bioengineering and the Senior Associate Vice Provost for Research at Stanford University. She is a founding member of the Stanford Bioengineering Department and served as its Chair from 2017 to 2022. Her research expertise and translational interests span protein-based drug discovery and development for applications in oncology and regenerative medicine. Dr. Cochran’s lab originally engineered the innovative tumor-targeting peptide integral to TwoStep’s platform. Dr. Cochran is a serial innovator and brings extensive company formation and entrepreneurial experience, having co-founded several biotech companies and Red Tree Venture Capital.
Co-Founder
Carolyn Bertozzi, PhD, is a Co-Founder of TwoStep Therapeutics and is the Anne T. and Robert M. Bass Professor of Chemistry at Stanford University and an Investigator of the Howard Hughes Medical Institute. She was awarded the 2022 Nobel Prize in Chemistry for the invention of bioorthogonal chemistry and is a world leader in antibody-drug conjugate technology. Dr. Bertozzi is an elected member of the National Academy of Medicine, the National Academy of Sciences, and the National Academy of Engineering and has been awarded the Welch Award in Chemistry, the Solvay Prize, the Wolf Prize, the Heineken Prize for Biochemistry and Biophysics and a MacArthur Foundation Fellowship, among many others. Her commitment to innovation extends beyond academia, as evidenced by her board memberships at Alnylam Pharmaceuticals, OmniAb and Xaira Therapeutics, and her previous service on the board of Lilly.
Co-Founder
Ronald Levy, MD, is a Co-Founder of TwoStep Therapeutics and is a medical oncologist and Professor of Medicine at Stanford University. Dr. Levy is a pioneer in the field of cancer immunotherapy. He was the first to successfully treat cancer with a monoclonal antibody, and went on to help develop Rituximab (Rituxan®), the first FDA-approved monoclonal antibody for cancer, which is still widely used to treat lymphoma today. Dr. Levy currently serves as the Associate Director of Translational Science for the Stanford Cancer Institute and previously served as the Chief of the Division of Oncology at Stanford University School of Medicine.
Strategic Advisor
Michael Ostrach, is a Strategic Advisor of TwoStep Therapeutics. He brings over 40 years of experience managing public, private, commercial and research-based biotechnology companies, including the initiation and execution of numerous public and private financings, partnerships and acquisitions. Mr. Ostrach previously served as the Chief Financial Officer, Chief Business Officer and General Counsel at Dynavax Technologies Corporation, a commercial biopharmaceutical company with a marketed vaccine. Earlier in his career, Mr. Ostrach held leadership roles at several biotechnology companies including Threshold Pharmaceuticals, Inc., Kosan Biosciences, Inc., Chiron Corporation and Cetus Corporation. Mr. Ostrach obtained a J.D. from Stanford Law School and a B.A. from Brown University.
